What was shown
The advanced reproductive age patient is not only a quantity problem — many present with reasonable antral follicle count, retrieve a normal number of oocytes, and still end the cycle with poor maturation and no euploid embryo. The talk reframes that picture as relative LH deficiency: the LH:FSH ratio drifts below 1 in the older patient, and the oocyte loses its competence support.
Key findings
Relative LH deficiency in patients over 38 affects oocyte quality more reliably than total oocyte yield. A high FSH dose without adequate LH support produces a paradoxical drop in mature-oocyte yield. The two-cell two-gonadotrophin model is most exposed at this age — theca-androgen supply, granulosa-aromatase activity and mitochondrial competence all depend on intact LH signalling.
What this means in practice
Measure LH and FSH on day 2-3 and compute the ratio. In patients 38+ with a low LH:FSH ratio, add recombinant LH or HMG to the protocol. Do not chase higher FSH alone in the older patient with a normal antral follicle count and a previous low-maturation cycle — the answer is in LH, not in dose.
Caveats
LH activity from HMG and recombinant LH is not pharmacokinetically identical; choice depends on patient and protocol. Mitochondrial decline with age sets a ceiling that no protocol fully escapes. Personalisation needs a previous cycle as anchor data.
The key practical tool is the LH:FSH ratio on cycle day 2–3: its drift below 1 in a patient of 38+ signals a relative LH deficiency that hits oocyte quality harder than number.
Hence the counter-intuitive conclusion: raising the FSH dose in such a patient with a normal antral pool and a prior low-maturity cycle is a mistake; the answer lies in adding LH (recombinant or hMG), not in the dose.
The upshot: in the older patient a normal "quantitative" response masks a qualitative deficit; the protocol should restore LH support of late maturation, even though the age-related mitochondrial decline sets a ceiling no regimen escapes.
With age, not only the quantity but also the quality of oocytes changes, and the hormonal profile shifts: basal FSH rises, the LH:FSH ratio falls, and a relative LH deficiency develops. In patients aged 38+ this weakens androgen support of theca cells and estradiol synthesis in the late follicular phase.
AMH and antral follicle count (AFC) describe the ovarian reserve but do not directly predict oocyte quality. A key factor in age-related decline is the mitochondrial competence of the oocyte: an energy deficit affects meiosis, chromosome segregation and fertilization capacity, clinically manifesting as a rise in aneuploidy.
The strategy in older patients is to add LH activity (recombinant LH or low-dose hCG, menotropins) to support steroidogenesis, individualize the starting dose and, if needed, accumulate oocytes and embryos. The goal is not the maximum number of follicles but the maximum number of competent oocytes per cycle.
An 18-oocyte cycle at 40 with a poor maturation rate is no longer surprising. Why advanced reproductive age is not only quantity but quality, what relative LH deficiency does to oocyte competence, and how to read the LH:FSH ratio when planning a stimulation in the over-38 patient.
-1.png&w=3840&q=75)
